Stay updated with breaking news from Roberto Giugliani. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HYOGO, Japan--(BUSINESS WIRE)--Feb 14, 2024--
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolledTopline data from the study, exp...
RAINBOW study design enables rapid advancement into the company's planned Phase 3 efficacy trial Azafaros B.V. today announced that the first patient has been enrolled into its Phase 2 RAINBOW
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease - read this article along with other careers information, tips and advice on BioSpace
REGENXBIO Inc. today announced a comprehensive program update to outline its progress and development plans for RGX-181 and RGX-381, both being developed as potential one-time gene therapies for the... | December 22, 2022